CICP11: A Drug Target / Disease Biomarker (G100288904)

Target Name: CICP11

NCBI ID: G100288904

CICP11

Other Name(s): Capicua transcriptional repressor pseudogene 11 | capicua transcriptional repressor pseudogene 11

CICP11: A Drug Target / Disease Biomarker

CICP11 is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the insulin secretion pathway, which is critical for regulating blood sugar levels. CICP11 has been identified as a potential drug target or biomarker for various diseases, including diabetes, obesity, and neurodegenerative disorders.

One of the unique features of CICP11 is its ability to interact with several different transcription factors, including activating the nuclear factor kappa B (NFkB) and the androgen receptor (AR). This interaction with these transcription factors allows CICP11 to regulate a wide range of cellular processes, including inflammation, cell survival, and metabolism.

CICP11 has been shown to play a key role in the regulation of pancreatic insulin secretion. In pancreatic cancer, CICP11 has been shown to be overexpressed, which can lead to increased insulin production and a higher risk of developing cancer. Additionally, CICP11 has been shown to be involved in the regulation of glucose metabolism, which is critical for the treatment of diabetes.

CICP11 has also been shown to be involved in the regulation of pain perception. In neuropathic pain models, CICP11 has been shown to play a critical role in the regulation of pain sensitivity and the modulation of pain transmission. This suggests that CICP11 may be a potential target for the treatment of neuropathic pain.

CICP11 has also been shown to be involved in the regulation of body weight and obesity. In obese individuals, CICP11 has been shown to be overexpressed, which can lead to increased insulin production and a higher risk of developing type 2 diabetes. Additionally, CICP11 has been shown to be involved in the regulation of energy metabolism, which is critical for the treatment of obesity.

In addition to its potential clinical applications, CICP11 has also been shown to be a valuable research tool for the study of insulin secretion and glucose metabolism. Its ability to interact with multiple transcription factors makes it a useful model for the study of gene regulation and cellular signaling. Additionally, its expression has been shown to be regulated by a wide range of factors, including diet, exercise, and environmental stress, which makes it an attractive candidate for the study of the role of lifestyle factors in disease.

In conclusion, CICP11 is a protein that has been shown to play a critical role in the regulation of insulin secretion, glucose metabolism, pain perception, and body weight. Its unique ability to interact with multiple transcription factors makes it a potential drug target or biomarker for a wide range of diseases. Further research is needed to fully understand the role of CICP11 in disease and to develop effective treatments.

Protein Name: Capicua Transcriptional Repressor Pseudogene 11

The "CICP11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CICP11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets